Biogen says litifilimab posts sustained skin clearance in 52-week Phase 2 cutaneous lupus study

By Public Technologies
  • Biogen reported 52-week Phase 2 AMETHYST data for litifilimab in cutaneous lupus erythematosus, previously presented at EADV 2026.
  • Results showed rapid symptom improvement for patients switching from placebo, with benefits sustained through one year of treatment.
  • More patients reached clearer skin over time, supporting litifilimab’s positioning as a potential first-in-class, once-monthly therapy.
  • Safety remained consistent with earlier studies, with no new safety signals over the extended treatment period.
  • Phase 3 results are expected in the first half of 2027, following FDA Breakthrough Therapy Designation granted in January 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610021120PRIMZONEFULLFEED9838232) on October 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.